<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92293">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01755754</url>
  </required_header>
  <id_info>
    <org_study_id>IPM 033</org_study_id>
    <nct_id>NCT01755754</nct_id>
  </id_info>
  <brief_title>Female Condom Functionality</brief_title>
  <official_title>A Multicenter, Open-label, Randomized, Two-period, Crossover Non-inferiority Trial to Assess the FunctionalityY of Female Condoms With a Silicone Elastomer Vaginal Ring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Partnership for Microbicides, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Partnership for Microbicides, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial being conducted to assess the total clinical failure rate and its components of a
      female condom used during vaginal intercourse in the presence and absence of the vaginal
      ring.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Total clinical failure rate</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Condom Functionality</condition>
  <arm_group>
    <arm_group_label>No ring - condom only</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo vaginal ring</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Female condom used with vaginal ring</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vaginal ring</intervention_name>
    <arm_group_label>placebo vaginal ring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Mutually monogamous heterosexual couples; current relationship ≥3 months; and who can
             give written informed consent;

          2. Age ≥18 to ≤45 years (females) or ≥18 to ≤55 years (males) at time of the screening
             visit;

          3. Healthy on the basis of medical history;

          4. Not at risk of pregnancy, i.e., female is surgically sterile, using an IUD, or using
             effective hormonal contraception, or has a vasectomized partner. The use of vaginal
             contraceptive rings will not be allowed;

          5. Sexually active and agree to have at least 8 acts of penile-vaginal intercourse using
             a study condom over 2 periods of up to 4 weeks each;

          6. Agree to use only the female condoms provided by trial personnel during the time of
             participation and not to use male condoms during the trial.  Additional lubricant
             will be provided; use of non-study lubricants will not be allowed;

          7. Agree to not use genital jewelry or other vaginal products, except menstrual
             absorption products (e.g., tampons) and study lubricant during the trial;

          8. Available for all visits and consent to follow all procedures scheduled for the
             trial;

          9. At low risk for HIV infection.

        Exclusion Criteria:

          1. Males with untreated erectile dysfunction;

          2. Female with positive pregnancy test;

          3. Either partner allergic or hypersensitive to vaginal lubricants such as Astorlige ®

          4. Either partner not willing to refrain from wearing  genital piercing jewelry for the
             duration of the study

          5. History by self-report of recurrent or a recently-treated (within past 2 weeks)
             sexually transmitted infection (e.g. gonorrhea, syphilis, chlamydia) or HIV(+);

          6. Consistently using male or female condoms for protection against sexually transmitted
             infection;

          7. Either partner taking any topical or oral medication to treat a urogenital condition
             at enrollment, except medication for the male partner to treat erectile dysfunction
             (e.g., tadalafil, sildenafil);

          8. Either partner with a self-reported or clinically diagnosed urogenital condition
             (e.g. itching, burning, irritation, etc.) that, in the opinion of the Investigator,
             could affect use of the study condoms or ability to interpret trial data;

          9. Females, based on findings from a pelvic examination, who are not suitable candidates
             for wearing the vaginal ring (anatomical condition, current vaginal infection, etc.)

         10. Current participation in a study or other research involving a drug, device or other
             product;

         11. Any condition(s) that, in the opinion of the Investigator, might interfere with
             adherence to trial requirements or evaluation of the trial objectives.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ron Frezieres</last_name>
    <phone>213-386-5614</phone>
    <phone_ext>4403</phone_ext>
    <email>frezieres@cfhc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>California Family Health Council</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seline Guidotti</last_name>
      <phone>877-437-2007</phone>
    </contact>
    <contact_backup>
      <last_name>Kate Hodges</last_name>
      <phone>800-300-5767</phone>
    </contact_backup>
    <investigator>
      <last_name>Ron Frezieres</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 2, 2013</lastchanged_date>
  <firstreceived_date>December 14, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
